Viral and Non-Viral Vector Manufacturing Market Size, Share & Trends Analysis Report By Vector type (Viral Vector, Non-Viral Vector), By Disease (Cancer, Genetic Disease, Infectious Disease, Cardiovascular Disease, Other Diseases), By Application, By Region, And By Segment Forecasts, 2025-2034

Global Viral and Non-Viral Vector Manufacturing Market Size is valued at USD 8.0 Billion in 2024 and is predicted to reach USD 56.8 Billion by the year 2034 at a 21.9% CAGR during the forecast period for 2025-2034.

Viral vectors are genetically modified viruses utilised as carriers for introducing exogenous genetic material into cells through their viral genome. In contrast, nonviral vectors encompass a range of chemical vectors, including inorganic particles, lipid-based vectors, polymer-based vectors, and peptide-based vectors, which also serve as vehicles for delivering foreign genetic material into cells.

Viral vectors are used to convey genetic material into cells and have become a popular method for gene transfer due to their high transfection effectiveness, sustained gene expression, and efficient gene delivery. Plasmid DNA is essential in the healthcare industry, as it is used as a therapeutic agent in gene therapy and the production of vaccine antigens.

The growing usage of gene therapy to treat viral infections such as adeno-associated viruses, poxviruses, herpes simplex viruses, and retroviruses is expected to boost gene therapy acceptance, which will help to push viral vector and plasmid DNA manufacturing market expansion. Furthermore, demand for viral vectors and plasmid DNA production is expected to rise in the next years due to the rising need for DNA treatments and cancer research R&D. The partnership focused on increasing the chromatographic separation of AAV-based vectors using several AAV types. As a result, such collaborations are expected to improve the manufacturing efficiency and scalability of gene therapies, allowing for the global availability of viral vectors and creating lucrative market opportunities. Gene treatments are being developed via viral vectors and plasmid DNA, which is one of the fastest expanding areas in advanced medicines.

Healthcare companies are developing DNA vectors for vaccine manufacturing. Many challenges affect the manufacturers of viral vectors and plasmid DNA whose products are in phase III clinical trials and commercial production of viral vectors. Many existing vector production technologies are inadequate in terms of productivity, efficiency, stability, and other factors.

• In Jan 2023, Charles River Laboratories and Rznomics, a South Korean biopharma, have engaged into a partnership to develop and manufacture viral vectors for a gene therapy to treat liver cancer. The technology of Rznomics employs an adenoviral vector that expresses a hTERT-targeting ribozyme to treat hepatocellular carcinoma patients, who account for 80% of primary liver cancer cases worldwide.

• In Dec 2022, The GMP lentivirus production service was developed by Creative Biogene to accelerate the advancement of gene and cell therapies. To certify the quality, safety, and consistency of clinical products for gene therapy clinical trials, Creative Biogene incorporates advanced lentiviral production technology and implements a comprehensive GMP programme. Creative Biogene has developed a patented method that demonstrates remarkable efficacy in the production of ultra-high titer lentiviral vectors, including those suitable for clinical applications.

Market Segmentation:

The Viral and Non-Viral Vector Manufacturing market is segmented based on vector type, diseases, and application. Based on vector type, the market is segmented as Viral Vector (Adenoviral Vector, Retroviral Vector, Adeno-Associated Viral Vector, Lentiviral Vector, Vaccinia Viral Vector, Other Viral Vector), Non-Viral Vectors, (Plasmid DNA, Lipid-Based Non-Viral Vector, Polymer-Based Non-Viral Vector, Other Non-Viral Vector (Peptide-Based and Hybrid/Combination)). Based on application, the market is categorized into gene therapy, vaccinology, cell therapy and other applications. The market is segmented based on diseases includes Cancer, Genetic Disorder, and Infectious diseases.

Based On Viral Vectors, The Non-Viral Vectors Segment Is Accounted As A Major Contributor In The Viral And Non-Viral Vector Manufacturing Market

The Non-Viral vectors category is expected to hold a significant share in the global Viral and Non-Viral Vector Manufacturing market in 2021. The COVID-19 viral vector vaccines use non-replicating viral vectors. The market will continue to increase as more non-viral vectors are used in vaccine development in the occurrence of a pandemic. According to a PubMed paper published in 2017, the development of non-viral DNA vectors has progressed substantially, particularly in the reduction of plasmid vector length. This factor is also playing a vital role in the segment's growth.

Vaccinology Segment Witnessed Growth At A Rapid Rate.

The vaccinology segment is projected to proliferate in the global Viral and Non-Viral Vector Manufacturing market. This is because viral vectors are regularly used in vaccine development due to their efficiency benefits. Positives include the ability to encourage a comprehensive immunological response, as well as the safety profiles and convenience of manufacture. Furthermore, the European Medicines Agency (EMA) has approved the use of AAV in clinical trials since it may express epitomal genes without integrating into the host genome. In addition, attempts to design and enhance immunization schedules will drive the development of novel vaccines, especially in countries such as the US, Germany, the UK, China, and India.

In The Region, The North America Viral And Non-Viral Vector Manufacturing Market Holds A Significant Revenue Share.

The North America Viral and Non-Viral Vector Manufacturing market is expected to register the highest market share in terms of revenue soon due to the presence of a significant number of research centres engaged in advanced therapy research and development. Furthermore, the construction of manufacturing units by competitors from other countries in North America is a driving force behind the region's market expansion. In addition, Asia Pacific is projected to grow at a rapid rate in the global Viral and Non-Viral Vector Manufacturing market. This is due to the creation of accelerated approval processes, the growing pool of patient population, growing private and government investments, and rising healthcare requirements. Furthermore, the unmet demands in the field of personalized medicine are driving the growing demand for viral vectors.

Competitive Landscape

Some major key players in the Viral and Non-Viral Vector Manufacturing Market:

• Boehringer Ingelheim,
• Catalent, Inc.,
• FUJIFILM Holdings Corporation,
• Danaher Corporation,
• Rescript Biotech Corporation,
• Lonza Group AG,
• Merck Kagan Inc.,
• Oxford Biomedical plc,
• Sartorius AG,
• Takara Bio Inc,
• Thermo Fisher Scientific Inc,
• Wuxi Optec,
• Acuities Therapeutic,
• Evonik Industries AG,
• Exiled, Inc.,
• Entos Pharmaceuticals,
• Genevant Sciences GmbH,
• T&T Scientific Corporation,
• Moderna, Inc
• CureVac N.V.

Viral and Non-Viral Vector Manufacturing Market Report Scope